Verastem reports encouraging early data for KRAS G12D inhibitor in pancreatic cancer

Verastem Oncology disclosed early clinical results for its KRAS G12D inhibitor, which is being evaluated in more than 200 patients with advanced solid tumors, including metastatic pancreatic ductal adenocarcinoma.

The data indicated activity against pancreatic cancer, a disease where KRAS mutations are common and difficult to treat, suggesting the drug may have therapeutic potential.

The study is part of a broader early-phase program that also includes other tumor types, and the company will continue enrolling patients while planning to share more detailed outcomes as the trial advances.